Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B Streptococcus (GBS) vaccine candidate, GBS6, which is designed as a maternal immunization to protect infants against invasive GBS disease. The results reveal that the hexavalent vaccine generated a robust antigenic response in pregnant women, with antibodies efficiently transferred to infants, demonstrating its potential effectiveness.
Advancing to Phase III Development
Following the successful Phase II trial, Pfizer’s GBS vaccine candidate will now progress to Phase III of development. This advancement is a significant step towards potentially bringing a new vaccine to market aimed at preventing GBS-related diseases in infants.
Implications for Maternal and Infant Health
The Phase II data supports the potential of GBS6 as a maternal immunization, highlighting the vaccine’s ability to elicit a strong immune response and pass on protective antibodies to infants. This approach could provide a crucial tool in the fight against invasive GBS disease in newborns, contributing to maternal and infant health outcomes globally.-Fineline Info & Tech
